FIBROBLAST GROWTH FACTOR-23: A NOVEL BIOMARKER FOR CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE PATIENTS

Aikaterini Papagianni

Department of Nephrology, Aristotle University of Thessaloniki, General Hospital “Hippokratio”, Thessaloniki, Greece

Corresponding author: Aikaterini Papagianni, MD, PhD, Professor of Nephrology, Department of Nephrology, Aristotle University of Thessaloniki, General Hospital “Hippokratio”, 49 Konstantinoupoleos Str 54642, Thessaloniki, Greece, e-mail: aikpapag@otenet.gr

ABSTRACT

Fibroblast Growth Factor (FGF)-23 increase is considered one of the earliest biochemical abnormalities in chronic kidney disease-mineral bone disorder (CKD–MBD). Furthermore, accumulating data have provided evidence of a link between increased FGF-23 levels and cardiovascular morbidity and mortality in CKD patients as well as in several other populations including cardiology patients and general population. The cellular and molecular mechanisms underlying the deleterious effect of FGF-23 on the cardiovascular system are not yet completely defined and are the focus of intense research. However, animal and human studies have demonstrated important actions of FGF-23 in the heart and vessels through which could promote the development of cardiovascular complications in uremia. Moreover, significant interactions have been reported between FGF-23 and other well recognized cardiovascular risk factors such as renin-angiotensin system and inflammation which could account, at least in part, for the observed associations between FGF-23 and adverse clinical outcomes. Further studies are needed to clarify the mechanisms responsible for the pleiotropic actions of FGF-23 and moreover to identify whether it is a modifiable risk factor and a potential target of therapeutic interventions which could probably help to reduce the unacceptably high cardiovascular morbidity and mortality of CKD patients.

Key words: Fibroblast Growth Factor-23, chronic kidney disease

INTRODUCTION

Cardiovascular disease (CVD) remains the leading cause of increased morbidity and mortality for patients with chronic kidney disease (CKD) and particularly those on renal replacement therapy [1-4]. Undoubtedly, several traditional risk factors such hypertension, diabetes, dyslipidemia and reduced physical activity are over-represented in these patients populations. However, it appears that the above factors cannot fully account for the extremely high cardiovascular morbidity and mortality rates and risk stratification by Framingham predictive instrument is less accurate in these patients compared to the general population whereas modification of them has been shown to be of limited benefit in advanced CKD [5]. The above indicate that other non-traditional and uremia-related risk factors, including inflammation, oxidative stress, increased sympathetic activity, sodium-volume retention and particularly mineral and bone disorders (MBD), are important contributors to the increased risk of CVD and mortality. These pathways appear to promote the development of functional and histomorphological changes in the cardiovascular system through multiple and often overlapping mechanisms which up-to-now are poorly defined and are the focus of intense research.
Fibroblast growth factor-23 in patients with chronic kidney disease

Fibroblast growth factor (FGF)-23 is produced and secreted from osteoblasts and osteocytes in response to hyperphosphatemia and increased 1,25 dihydroxyvitamin D3 levels. FGF-23 concentrations increase progressively as glomerular filtration rate (GFR) declines and they can be up to 1000-fold higher in patients with end-stage renal disease (ESRD) compared with healthy individuals [6]. This increase is considered one of the earliest (if not the earliest) biochemical abnormality in CKD-MBD preceding alterations of other parameters of mineral and bone metabolism including 1,25 dihydroxyvitamin D3, parathyroid hormone and phosphate [7]. Of note, experimental studies showed that kidney has an important role in FGF-23 homeostasis by regulation of its plasma level and metabolism [8]. However, the role of kidney as a probable extraskeletal source of FGF-23 remains controversial. Thus, induced expression of FGF-23 has been reported in animal models of CKD [9,10] whereas a very recent study showed that kidney FGF-23 does not contribute to elevation of its circulating levels in uremia [11].

The classic target organs of FGF-23 are the kidneys and the parathyroid glands in which membrane bound Klotho protein functions as obligatory co-receptor to enhance the affinity of FGF receptors (FGFR) to FGF-23 [12]. In kidneys FGF-23 induces phosphaturia through suppression of the apical membrane expression of the sodium phosphate cotransporters NaPi-2a and NaPi-2c in renal proximal tubules. In addition, it decreases 1,25-dihydroxyvitamin D3 through direct inhibition of 1α-hydroxylase and increase of 24 hydroxylase, the enzyme responsible for its catabolism. In the parathyroid glands FGF-23 regulates parathormone (PTH) secretion through a mechanism which is not entirely clear. Studies have shown that FGF-23 suppresses PTH secretion both through Klotho-dependent and independent mechanisms whereas PTH stimulates its production. However, in advanced CKD stages, parathyroid glands become resistant to FGF-23 which fails to suppress PTH despite its significantly increased levels [12].

Over the past decade accumulating data suggest that FGF-23, particularly in supra-physiological concentrations as those observed in CKD patients, is a pleiotropic hormone influencing not only mineral metabolism but also cardiovascular function. Consequently, FGF-23 has been the focus of intense basic, translational and clinical research in nephrology and cardiology communities. Numerous studies have consistently demonstrated that FGF-23 levels are associated with future cardiovascular events and cardiovascular mortality independently of other traditional and uremia-related risk factors in patients with different CKD stages as well as in other populations including cardiology patients and general population [13-19]. Moreover, recently it has been shown that at least some of these actions are independent of Klotho although the underlying cellular and molecular mechanisms remain to be fully elucidated.

Fibroblast growth factor-23 and the heart

Left ventricular hypertrophy (LVH) is a common manifestation of CVD and its incidence is increasing along with deterioration of renal function. Moreover, LVH is associated with the development of congestive heart failure (CHF) and increased cardiovascular morbidity and mortality whereas its reversal is associated with improved clinical outcomes [20,21]. Several studies in CKD and cardiology patients as well as in elderly individuals showed an association between FGF-23 levels and left ventricular mass and ejection fraction [22-26]. Moreover, a study in patients with CKD stages 2-4 showed that elevated FGF-23 is more strongly associated with risk of CHF than atherosclerotic events (myocardial infarction, stroke and peripheral vascular disease) [27]. Interestingly, in vitro and in vivo studies have demonstrated that FGF-23 exerts a direct cardiotoxic effect since it promotes dose-dependently cardiomyocyte hypertrophy and left ventricular hypertrophy even in the absence of arterial hypertension which is the main risk factor for its development [28]. The above effect of FGF-23 on the heart was shown to be independent of Klotho and a recent in vitro study provided evidence that it is mediated through FGFR4 activation of the phospholipase Cγ/calcineurin/nuclear factor of activated T cells (NFAT) signaling pathway in cardiac myocytes, which has been previously reported to induce LVH [29]. The above mechanism was supported by an important recent autopsy study in patients with childhood-onset ESRD who died while receiving renal replacement therapy. The above study demonstrated that FGF-23 mRNA expression was higher in myocardium of CKD cases compared with controls free of heart or cardiac disease at the time of death. Moreover, FGF-23 mRNA expression was higher in cases with autopsy-proven LVH compared with cases without LVH and that
higher FGF-23 expression was correlated with higher cardiomyocyte cross-sectional area and higher cardiac B-type natriuretic peptide expression. In addition, although no differences were observed in FGFR1 expression in myocardial tissue from cases and controls, FGFR4 mRNA expression was higher in cases than controls and higher in LVH(+) cases compared with those without LVH where it was correlated positively with cardiomyocyte cross-sectional area and FGF23 expression. Finally, mRNA FGF-23 as well as myocardial expression of the regulatory subunit of calcineurin and NFAT were higher in cases with LVH as compared with those without LVH (30). Of note, previous studies in experimental CKD have shown that complete inhibition of FGF-23 activity prevents the development of LVH and secondary hyperparathyroidism but it is associated with increased mortality linked to hyperphosphatemia and vascular calcifications [31]. These findings suggest that blocking FGFR4 or its downstream signaling pathways could represent a better therapeutic approach to reduce cardiovascular mortality in CKD patients. Interestingly, specific inhibitors of FGFR4 have been developed and are currently in phase II clinical trials for solid tumors with FGFR4 genetic alterations. Although patients with CKD are excluded from these studies, data on the safety and tolerability of FGFR4 inhibitors in other patient populations could provide helpful information for the design of studies in CKD patients [32].

Apart from its hypertrophic effect on cardiac myocytes, experimental studies have demonstrated that FGF-23 regulates intracellular calcium influx and cardiomyocyte contractility suggesting that it is probably associated with the development of arrhythmias which are a major cause of death in patients with ESRD [33]. In accordance with the above, recent studies in dialysis and pre-dialysis patients but also in patients without renal function impairment have shown that FGF-23 levels are an independent prognostic factor of prevalent and incident atrial fibrillation which is also associated with increased morbidity and mortality in these patient populations [34,35].

**Fibroblast growth factor-23 and the vessels**

Several studies have investigated the probable association between circulating FGF-23 levels with endothelial dysfunction and the prevalence and severity of atherosclerotic and arteriosclerotic vascular changes in different patient populations. The results of the above studies vary depending on the population studied, the method used for the evaluation of atherosclerotic and arteriosclerotic vascular changes and the other risk factors, traditional and CKD-related, that were taken into account. Thus, in a community-based cohort of elderly subjects, higher FGF-23 levels were weakly associated with impaired both endothelial-dependent and endothelium-independent vasodilation. These associations were independent of gender, biochemical covariates and established cardiovascular risk factors and were stronger in subjects with normal renal function [36], in patients with stage 3 and 4 CKD the response of forearm blood flow to ischemia (flow-mediated vasodilation, FMD) was found to be significantly associated with FGF-23 levels after adjustment for classical risk factors, biomarkers of bone mineral metabolism, C-reactive protein (CRP) levels and homeostatic model assessment index [37]. Another study, reported improvement of FMD after kidney transplantation which was parallel to the dramatic decrease in FGF-23 levels as well to the reduction of serum phosphorus and the increase in 25 hydroxyvitamin D levels. In contrast, no independent association was observed between FMD changes with classical and CKD-related risk factors such as GFR, serum albumin, CRP and insulin resistance [38]. Moreover, a recent study showed improvement of Intima media thickness, a marker of early atherosclerosis, after renal transplantation which was strongly associated with the changes of CRP and FGF-23 levels. The above associations were largely independent from classical risk factors including blood pressure, LDL cholesterol and insulin resistance [39]. Finally, in a community-based cohort of elderly individuals, higher FGF-23 levels, particularly in subjects with estimated GFR (eGFR) <60 ml/min/1.73m², were found to be strongly associated with a significant increase in the risk of having a higher total body atherosclerosis score determined by a magnetic resonance imaging-based angiography. However, no independent relationship was observed between FGF-23 levels and the presence of atherosclerosis [40].

Arterial calcifications, both intimal (atherosclerotic) and medial (arteriosclerotic) are commonly observed in CKD patients, follow an accelerating course and contribute significantly to their increased cardiovascular morbidity and mortality [41]. Several studies examined the association between FGF-23 and the presence and extent of calcifications in the coronary arteries and
other vascular beds. In patients with normal kidney function who underwent coronary computed tomography, no correlation was found between FGF-23 levels and coronary artery calcification score or the presence of non-calcified plaques and coronary artery stenosis ≥50% [42]. In accordance with the above findings, another study in patients with preserved renal function reported no correlation between FGF-23 with either coronary artery obstruction or coronary artery calcification determined by coronary angiography and multislice computed tomography respectively [43].

In contrast, another study in patients undergoing coronary angiography reported a significant and independent from traditional risk factors association between FGF-23 levels and the stenosis scores as well as the plaque and dense calcium volumes [44]. Similarly, a study in patients with CKD (eGFR 30-90 ml/min/1.73m²) showed a significant association between FGF-23 levels and the coronary artery disease extent, assessed by coronary angiography, after adjustment for traditional and uremia-related risk factors including gender, arterial hypertension, HDL cholesterol, eGFR and PTH [45]. In addition, a study in hemodialysis patients showed an association of FGF-23 levels with coronary calcification scores assessed by multislice computed tomography but not with medial calcifications assessed histologically in peripheral arteries [46]. Finally, in another study in HD patients a significant and independent association was observed between FGF-23 and aortic calcification index assessed by non-contrast computed tomography of the abdominal aorta [47]. However, some experimental studies failed to demonstrate an effect of FGF-23 on calcification of vascular smooth muscle cells [48]. In contrast, another study reported that FGF-23 promotes phosphate-induced vascular calcification in uremic rat aortic rings and vascular smooth muscle cells by a Klotho- and ERK1/2-dependent pathway [49]. Finally, in a recent study mRNA FGF-23 or expression was not detected in human or mouse vascular smooth muscle cells, or normal or calcified mouse aorta. In addition, in vitro FGF-23 had no effect on phosphate uptake or phosphate-induced calcification regardless of phosphate concentration or even in the presence of its co-receptor Klotho [50]. Finally, the largest up-to-now studies in CKD patients failed to demonstrate a significant and independent association between FGF-23 concentrations with the presence and extent of coronary artery or thoracic aorta calcification assessed by computed tomography [50] and with the large and small arteries elasticity, pulse pressure and ankle-brachial index [51]. Overall, at the present there are no studies supporting a direct effect of FGF-23 on vascular function but clearly further studies are needed to identify its putative role in the development and progression of cardiovascular complications in CKD patients.

**Fibroblast growth factor-23 and other CKD-related cardiovascular risk factors**

Several experimental and human studies have shown significant interactions between FGF-23 and other well recognized CKD-related cardiovascular risk factors including renin-angiotensin system, sodium and volume retention and inflammation which could underlie the link between FGF-23 and cardiovascular complications.

Recent studies demonstrated that FGF-23 not only suppresses renal phosphate reabsorption in renal proximal tubules but also regulates renal sodium and calcium handling in renal distal tubules. FGF-23 was shown to activate with-nolysine kinase 4 (WNK4), a central molecule for trafficking of ion channels in renal epithelium, leading to increased apical membrane abundance of the Na(+):Cl(-) co-transporter (NCC) and of the transient receptor potential vanilloid-5 (TRPV5) in renal distal tubules. The latter in turn result in increased cellular uptake of sodium and calcium respectively [52,53]. In accordance with the effect of FGF-23 on sodium homeostasis and consequently on the regulation of plasma volume and blood pressure, normal mice injected with recombinant FGF-23 developed volume expansion, hypertension and heart hypertrophy after only 5 days of treatment. The above effects of FGF-23 were prevented by co-administration of NCC inhibitor chlorothiazide suggesting that increased NCC-mediated sodium reabsorption plays a central role in FGF-23-induced hypertension (52). The above FGF-23 action represent another pathway through which its excess levels in CKD patients may be linked to the development of arterial hypertension, LVH and adverse clinical outcomes.

As mentioned above, in CKD patients, 1,25 vitamin D concentrations are usually low as a result of both reduced functional nephron number and suppression of its production by increased FGF-23 levels. Vitamin D is a well-recognized regulator of endothelial function and moreover it was found to stimulate the production of renin in the kidney and consequently to lead in increased angiotensin II levels [54,55]. Thus, it is plausible...
that some of the effects of FGF-23 on the cardiovascular system are at least partly mediated through suppression on active vitamin D. Moreover, FGF-23 may also induce endothelial dysfunction by directly interfering with nitric oxide (NO)-mediated vasodilation. Asymmetric dimethylarginine (ADMA), the most abundant endogenous inhibitor of NO synthase, has been reported to be a risk factor for endothelial dysfunction and atherosclerosis [56-58]. An experimental study demonstrated that FGF-23 increase superoxide levels in endothelial cells and aortic rings, inhibits nitric oxide bioavailability and causes endothelial dysfunction in mouse aorta [59]. Moreover, in an aforementioned study in CKD patients, FGF-23 levels were found to be associated with endothelium-dependent vasodilation independently of several risk factors [37]. However, adjustment for ADMA significantly attenuated the above link suggesting that nitric oxide may, in part, mediate the vascular effects of FGF-23 in CKD patients.

As mentioned above, FGF-23 has been shown to increase apical membrane expression of TRPV5, a glycoprotein essential for apical entry of calcium in calcium-transporting renal epithelial cells [53]. In hyperphosphatemic states, increased FGF-23 levels similarly to PTH, the other phosphaturic hormone, may help to conserve calcium despite FGF-23-induced 1,25-dihydroxyvitamin D3 suppression. However, it cannot be ruled out that in CKD populations with chronically excessive FGF-23 levels, calcium retention may contribute to the development of vascular calcifications.

Finally, a link has been noted between FGF-23 and inflammation which is also a risk factor for atherosclerosis, vascular calcifications and mortality. In patients with CKD stages 2 to 4, elevated FGF-23 levels were found to be associated with higher IL-6, TNF-α, CRP and fibrinogen levels independently of renal function and other known covariates of FGF-23 and inflammation [60]. In addition, recent experimental data demonstrated that inflammation directly stimulates FGF-23 transcription and protein expression in osteocyte cell lines and increases circulating FGF-23 levels in animals with and without CKD in part through a hypoxia-inducible factor 1α-depending mechanism. Conversely, elevated FGF-23 was found to induce hepatic production of IL-6 and CRP through an FGFR4-dependent but Klotho-independent mechanism [61,62]. Overall, the results of the above studies suggest the presence of a positive feedback loop between inflammation and elevated FGF-23 levels in CKD. However, although FGF-23 and inflammation appear to directly increase one another, a very recent study provided evidence that the above factors have an almost additive impact on mortality suggesting that they may have distinct downstream effects that account for their association with adverse clinical outcomes [63].

CONCLUSIONS

FGF-23 is a pleiotropic hormone with multiple actions on the heart and vessels and it is associated with adverse cardiovascular outcomes. Further understanding of the cellular and molecular mechanisms underlying these off-target effects of FGF-23 on the cardiovascular system would help to develop novel therapeutic strategies that could reduce the unacceptably high rates of cardiovascular morbidity and mortality of CKD patients. Moreover, clinical studies are required to determine whether decrease of excessive FGF-23 production by several approaches or specific inhibition of its action on cardiovascular tissues would improve cardiovascular outcomes in CKD patients.

REFERENCES


6. Larsson T, Nisbeth U, Ljunggren O, Juppnner H, Jonsson KB. Circulating concentration of


ФИБРОБЛАСТЕН ФАКТОР НА РАСТ-23: НОВ БИОМАРКЕР ЗА КАРДИОВАСКУЛЯРНИ БОЛЕСТИ КАЈ ПАЦИЕНТИ СО ХРОНИЧНА БУБРЕЖНА БОЛЕСТ

Екатерини Папајани

Клиника за нефрологија, Аристотелов университет во Солун, Општа болница „Хипократио“, Солун, Грција

Резиме

Зголемувањето на фибробластниот фактор на раст (FGF) -23 се смета за една од најраните биохемиски абнормалности кај хроничните бубрежни болести–минерално коскено нарушување (CKD-MBD). Исто така, собраните податоци даваат доказ за врска меѓу зголемените нивоа на FGF-23 и кардиоваскуларниот морбидитет и морталитет кај пациенти со хроничните бубрежни болести, како и кај неколку други популации, вклучувајки ги пациенти на кардиологија и општата популација. Клеточните и молекуларните механизми што се во основата на штетниот ефект на FGF-23 за кардиоваскуларниот систем сè уште не се целосно дефинирани и се во фокусот на интензивни истражувања. Сепак, животинските и човечките студии покажале значајни дејствувања на FGF-23 во срцето и крвните садови преку кои може да се промовира развојот на кардиоваскуларните компликации кај уремија. Покрај тоа, значајни интеракции се забележани меѓу FGF-23 и други добро познати кардиоваскуларни фактори на ризик како што се системот ренин-ангиотензин и воспалението, што дедумно може да даде одговор за разгледуваната поврзаност меѓу FGF-23 и негативните клинички резултати. Понатамошни студии се потребни за да се разјаснат механизмите одговорни за плетотропските активности на FGF-23 и за да се утврди дали тоа е променлив фактор на ризик и потенцијална цел за терапевтски интервенции што веројатно може да помогне да се намали не-прифатливо високот кардиоваскуларен морбидитет и морталитет на пациентите со хроничните бубрежни болести.

Ключни зборови: Фибробластен фактор на раст-23, хронични бубрежни болести